FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:2070-2072 December 19, 2002 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Mora-Duarte, J. PubMed Citation

Candida species are now the fourth leading cause of nosocomial bloodstream infection in the United States, exceeded in some series only by Staphylococcus aureus, coagulase-negative staphylococcus, and enterococcus species.^1,2 Wey and colleagues estimate the attributable mortality of candidemia at 38 percent.³ Candidemia is a surrogate marker for the presence of deeply invasive candidiasis, particularly in immunocompromised hosts.⁴ In patients with untreated or inadequately treated candidemia, the rate of clinically overt complications, including endophthalmitis, endocarditis, septic arthritis, and renal candidiasis, may be as high as 15 percent. Candidemia may be complicated by chronic disseminated candidiasis in neutropenic hosts and by meningoencephalitis . . . [Full Text of this Article]

Related Letters:

Caspofungin versus Amphotericin B for Invasive Candidiasis
Brown A. L., Greig J. R., Kartsonis N. A., Perfect J., Walsh T. J.
Extract | Full Text | PDF  
N Engl J Med 2003; 348:1287-1288, Mar 27, 2003. Correspondence

This article has been cited by other articles:

• Reboli, A. C., Rotstein, C., Pappas, P. G., Chapman, S. W., Kett, D. H., Kumar, D., Betts, R., Wible, M., Goldstein, B. P., Schranz, J., Krause, D. S., Walsh, T. J., the Anidulafungin Study Group, (2007). Anidulafungin versus Fluconazole for Invasive Candidiasis. NEJM 356: 2472-2482 [Abstract] [Full Text]  
• Baker, L. G., Specht, C. A., Donlin, M. J., Lodge, J. K. (2007). Chitosan, the Deacetylated Form of Chitin, Is Necessary for Cell Wall Integrity in Cryptococcus neoformans. Eukaryot Cell 6: 855-867 [Abstract] [Full Text]  
• Clancy, C. J., Huang, H., Cheng, S., Derendorf, H., Nguyen, M. H. (2006). Characterizing the Effects of Caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata Isolates by Simultaneous Time-Kill and Postantifungal-Effect Experiments.. Antimicrob. Agents Chemother. 50: 2569-2572 [Abstract] [Full Text]  
• Bow, E. J. (2006). Of Yeasts and Hyphae: A Hematologist's Approach to Antifungal Therapy. ASH Education Book 2006: 361-367 [Abstract] [Full Text]  
• Petraitiene, R., Petraitis, V., Kelaher, A. M., Sarafandi, A. A., Mickiene, D., Groll, A. H., Sein, T., Bacher, J., Walsh, T. J. (2005). Efficacy, Plasma Pharmacokinetics, and Safety of Icofungipen, an Inhibitor of Candida Isoleucyl-tRNA Synthetase, in Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 49: 2084-2092 [Abstract] [Full Text]  
• Kirby, A, Chapman, C, Hassan, C, Burnie, J (2004). The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum. J. Clin. Pathol. 57: 764-765 [Abstract] [Full Text]  
• Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M., Henkel, T. (2004). Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia. Antimicrob. Agents Chemother. 48: 2021-2024 [Abstract] [Full Text]  
• Brown, A. L., Greig, J. R., Kartsonis, N. A., Perfect, J., Walsh, T. J. (2003). Caspofungin versus Amphotericin B for Invasive Candidiasis. NEJM 348: 1287-1288 [Full Text]  
• (2003). Caspofungin: An Effective New Treatment for Invasive Candidiasis. JWatch Infect. Diseases 2003: 3-3 [Full Text]